Boston Partners Sells 1,307,291 Shares of Sanofi (NASDAQ:SNY)

Key Points

• Boston Partners has reduced its stake in Sanofi by 24.2%, selling 1,307,291 shares to hold 4,089,240 shares, which are now valued at approximately $226.7 million.
• Sanofi reported a $0.90 EPS for the last quarter, missing analysts' expectations of $0.96, while maintaining a revenue of $11.34 billion, surpassing the consensus estimate of $9.91 billion.
• Several analysts have issued ratings on Sanofi, with a consensus rating of "Buy"** and a price target of $62.00, indicating positive sentiment towards the stock.

Boston Partners lessened its stake in Sanofi (NASDAQ:SNY - Free Report) by 24.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,089,240 shares of the company's stock after selling 1,307,291 shares during the quarter. Boston Partners owned about 0.16% of Sanofi worth $226,692,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Price T Rowe Associates Inc. MD lifted its position in shares of Sanofi by 88.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after buying an additional 5,091,304 shares during the last quarter. Nuveen LLC bought a new position in shares of Sanofi in the first quarter worth about $177,831,000. Federated Hermes Inc. boosted its stake in shares of Sanofi by 58.5% in the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company's stock valued at $218,933,000 after purchasing an additional 1,456,269 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Sanofi by 969.6% during the 4th quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company's stock valued at $45,850,000 after purchasing an additional 861,770 shares during the last quarter. Finally, Regal Partners Ltd bought a new stake in shares of Sanofi during the 4th quarter valued at approximately $35,034,000. Institutional investors and hedge funds own 14.04% of the company's stock.

Analysts Set New Price Targets

SNY has been the subject of a number of research reports. Barclays reiterated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Sanofi in a report on Tuesday, August 5th. Guggenheim reissued a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Finally, Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Two analysts have rated the stock with a hold rating, five have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $62.00.

Sanofi Trading Up 1.5%

Shares of SNY stock traded up $0.73 during mid-day trading on Friday, reaching $49.77. The stock had a trading volume of 2,021,563 shares, compared to its average volume of 2,641,391. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The stock's 50-day moving average price is $48.57 and its two-hundred day moving average price is $51.83. The firm has a market capitalization of $122.21 billion, a PE ratio of 11.96, a price-to-earnings-growth ratio of 1.19 and a beta of 0.48. Sanofi has a 52-week low of $44.73 and a 52-week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). The company had revenue of $11.34 billion during the quarter, compared to analysts' expectations of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%. Sanofi's revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.73 EPS. Equities analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.